Oncology - Lung
ASCO Guideline: Management of dyspnea in advanced cancer
24 Feb, 2021 | 02:10h | UTCManagement of Dyspnea in Advanced Cancer: ASCO Guideline – Journal of Clinical Oncology
Commentary on Twitter (thread – click for more)
1/ How can we better manage dyspnea in people with advanced cancer?
Wonderful to see this new @ASCO Guideline out.
Led by Drs. @DrDavidHui and @campbell_meg #supponc #pallonc
Full text: https://t.co/qbdhzbibKw pic.twitter.com/f2Qf6GswvK
— Arjun Gupta (@guptaarjun90) February 23, 2021
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
19 Feb, 2021 | 02:04h | UTC
RCT: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%
18 Feb, 2021 | 02:34h | UTC
Commentary on Twitter
Phase 3 trial suggests #cemiplimab could be used as new first-line monotherapy option for patients with advanced non-small-cell #lungcancer with PD-L1 of at least 50%—it improved overall & progression-free survival compared with chemotherapy. Read https://t.co/O06Of6wx07 pic.twitter.com/KtQ24lEoR5
— The Lancet (@TheLancet) February 17, 2021
Radiation therapy for small-cell lung cancer: ASCO Guideline endorsement of an ASTRO Guideline
29 Jan, 2021 | 01:27h | UTC